1. Home
  2. HURN vs AKRO Comparison

HURN vs AKRO Comparison

Compare HURN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Huron Consulting Group Inc.

HURN

Huron Consulting Group Inc.

HOLD

Current Price

$180.19

Market Cap

2.8B

ML Signal

HOLD

Logo Akero Therapeutics Inc.

AKRO

Akero Therapeutics Inc.

HOLD

Current Price

$54.65

Market Cap

4.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HURN
AKRO
Founded
2002
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
4.5B
IPO Year
2004
2019

Fundamental Metrics

Financial Performance
Metric
HURN
AKRO
Price
$180.19
$54.65
Analyst Decision
Strong Buy
Buy
Analyst Count
4
11
Target Price
$190.25
$73.56
AVG Volume (30 Days)
134.5K
2.4M
Earning Date
10-28-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
32.32
N/A
EPS
5.98
N/A
Revenue
$1,618,977,000.00
N/A
Revenue This Year
$14.19
N/A
Revenue Next Year
$9.49
N/A
P/E Ratio
$30.01
N/A
Revenue Growth
12.67
N/A
52 Week Low
$118.25
$21.34
52 Week High
$180.29
$58.40

Technical Indicators

Market Signals
Indicator
HURN
AKRO
Relative Strength Index (RSI) 74.72 68.63
Support Level $168.79 $54.30
Resistance Level $166.87 $54.70
Average True Range (ATR) 4.57 0.17
MACD 1.02 -0.10
Stochastic Oscillator 94.85 71.07

Price Performance

Historical Comparison
HURN
AKRO

About HURN Huron Consulting Group Inc.

Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Share on Social Networks: